News
Blow to Biogen as ALS hope tofersen flunks phase 3 trial
Already struggling to make headway with its recently launched Alzheimer's drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral sclerosis
